Triple-negative breast cancer (TNBC) is defined by a lack of expression of estrogen receptors (ER), progesterone receptors (PR), and an amplification or overexpression of human epidermal growth factor receptor type 2 (HER2), and accounts for 10–15% of breast cancer cases [1,2]. This evidence concerns the gene ESR1 and breast carcinoma.